CDK4-6 inhibition in luminal breast cancerReport as inadecuate

CDK4-6 inhibition in luminal breast cancer - Download this document for free, or read online. Document in PDF available to download.

memo - Magazine of European Medical Oncology

, Volume 9, Issue 2, pp 76–81

First Online: 20 June 2016Received: 03 March 2016Accepted: 24 May 2016DOI: 10.1007-s12254-016-0268-2

Cite this article as: Gampenrieder, S.P., Rinnerthaler, G. & Greil, R. memo 2016 9: 76. doi:10.1007-s12254-016-0268-2 Summary

Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease. Combination strategies of endocrine therapy with targeted agents are aimed to overcome endocrine resistance. The selective CDK4-6 inhibitor palbociclib has shown promising results in metastatic luminal breast cancer when used in combination with endocrine therapy both in the first-line setting as in pretreated women. The drug showed a manageable safety profile with uncomplicated neutropenia as the most frequent side effect. Approval was already granted in the US and is also awaited during 2016 for Europe.

KeywordsCDK4-6 inhibitors Palbociclib Ribociclib Abemaciclib Endocrine resistance Authors’ contributions. All authors: data analysis and interpretation, final approval of manuscript; S. P. Gampenrieder: conception and design, collection and assembly of data, Manuscript writing; G. Rinnerthaler: manuscript writing, critical revising of the manuscript, critical revising of the manuscript; R. Greil: critical revising of the manuscript

Download fulltext PDF

Author: Simon Peter Gampenrieder - Gabriel Rinnerthaler - Richard Greil



Related documents